How has AstraZenca Pharma India Ltd. (ASTRAZEN) been performing? We dig into revenue, profitability, valuation, and ownership trends.
AstraZenca Pharma Revenue Trend
AstraZenca Pharma India Ltd. clocked ₹1,716 Cr in revenue for FY2025, up 32.5% from FY2024.
AstraZenca Pharma India Ltd.'s revenue grew from ₹517 Cr to ₹1,716 Cr at a 12.7% CAGR over 10 years — a pace most companies would be happy with.
With a top line of ₹1,716 Cr, AstraZenca Pharma India Ltd. operates at a mid-sized scale within the pharmaceuticals sector.
The consistency stands out: 3 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,716 Cr | +32.5% |
| FY2024 | ₹1,296 Cr | +29.2% |
| FY2023 | ₹1,003 Cr | +24.5% |
| FY2022 | ₹806 Cr | -2.5% |
| FY2021 | ₹826 Cr | — |
View AstraZenca Pharma India Ltd.'s full 10-year revenue trend with CAGR analysis →
AstraZenca Pharma Profitability
At ₹116 Cr, AstraZenca Pharma India Ltd.'s FY2025 net profit was 28.3% below what it earned in FY2024.
The company's net margin contracted to 6.7% in FY2025 from 12.5% in FY2024.
The diluted EPS figure moved down to ₹46.30 in FY2025, against ₹64.60 posted in FY2024.
Is AstraZenca Pharma Undervalued
AstraZenca Pharma India Ltd. shares are currently trading at ₹8,300.00.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
AstraZenca Pharma Shareholding Pattern
Promoters haven't moved — their 75.0% holding has been unchanged for 4 quarters.
Foreign institutional investors (FIIs) held 2.7% as of June 2026, down from 2.7% a year ago.
Domestic institutions moved their stake up to 6.1% from 5.3% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 75.0% | 2.7% | 6.1% | 16.2% |
| Mar 2026 | 75.0% | 2.8% | 5.8% | 16.4% |
| Dec 2025 | 75.0% | 2.7% | 5.6% | 16.7% |
| Sep 2025 | 75.0% | 2.7% | 5.3% | 17.0% |
Track quarterly shareholding changes for AstraZenca Pharma India Ltd. →
AstraZenca Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹15.18B (up 40.8% YoY from ₹10.78B).
Top categories: Inventories (36.1%), Cash & ST Investments (35.4%), Other Assets (14.5%).
Of the ₹15.18B in liabilities and equity, 50.7% is shareholder equity, 2.4% is interest-bearing debt, and 46.9% is operating liabilities. Over the year, debt is up 678.4% and equity is up 8.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.37B |
| Receivables | 1.85B |
| Inventories | 5.49B |
| Property, Plant & Equipment | 278.80M |
| Intangibles & Goodwill | 6.60M |
| Other Assets | 2.20B |
| Category | Value |
|---|---|
| Equity | 7.70B |
| Short-term Debt | 62.80M |
| Long-term Debt | 294.50M |
| Trade Payables | 4.56B |
| Other Liabilities | 2.56B |
AstraZenca Pharma at a Glance
Pulling it all together, here's what the numbers say about AstraZenca Pharma India Ltd. (ASTRAZEN) heading into the next fiscal year.
Revenue of ₹1,716 Cr in FY2025, up 32.5% year-over-year.
Long-term revenue has been compounding at 12.7% annually over 10 years.
The company is profitable, with a net margin of 6.7% and net income of ₹116 Cr.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for AstraZenca Pharma India Ltd. includes three valuation models, decade-long financials, and insider activity.